Endocyte, Inc.

16 patents currently held · Updated Nov 14, 2026

4 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

Ending by 2030

Sep 2029

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

2 fees due Mar 19 to 24, 2027 · next Mar 19
1 fee due Apr 10, 2027
The maintenance fee for Methods of Use for Car T Cells (US 11,779,602) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
1 fee due May 24, 2027
The maintenance fee for Folate receptor binding conjugates of antifolates (US 9,192,682) comes due May 24, 2027. Unpaid by Nov 24, 2027, it lapses early.
1 fee due Oct 21, 2027
The maintenance fee for Conjugates for treating diseases (US 10,624,972) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 term has ended since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 8,546,425	Folate receptor binding conjugates of antifolates In force (reinstated) Term ends Sep 17, 2029 · From the USPTO record	In force (reinstated)	Term ends Sep 17, 2029	From the USPTO record
US 9,192,682	Folate receptor binding conjugates of antifolates In force Term ends Sep 17, 2029 · From the USPTO record	In force	Term ends Sep 17, 2029	From the USPTO record
US 9,549,992	Folate Receptor Binding Conjugates of Antifolates In force Term ends Sep 17, 2029 · Medium confidence	In force	Term ends Sep 17, 2029	Medium confidence
US 11,219,622	Folate Receptor Binding Conjugates of Antifolates In force Term ends Sep 17, 2029 · Medium confidence	In force	Term ends Sep 17, 2029	Medium confidence
US 9,636,413	Conjugates for Treating Diseases Caused by Psma Expressing Cells In force Term ends Nov 14, 2033 · High confidence	In force	Term ends Nov 14, 2033	High confidence
US 9,782,493	Conjugates for Treating Diseases Caused by Psma Expressing Cells In force Term ends Nov 14, 2033 · High confidence	In force	Term ends Nov 14, 2033	High confidence
US 10,912,840	Conjugates for Treating Diseases Caused by Psma Expressing Cells In force Term ends Feb 17, 2034 · High confidence	In force	Term ends Feb 17, 2034	High confidence
US 10,624,972	Conjugates for treating diseases In force Term ends Mar 13, 2035 · From the USPTO record	In force	Term ends Mar 13, 2035	From the USPTO record
US 10,188,759	Conjugates for imaging In force Term ends Jan 6, 2036 · From the USPTO record	In force	Term ends Jan 6, 2036	From the USPTO record
US 10,420,850	Method of imaging with a chelating agent In force Term ends Oct 8, 2036 · From the USPTO record	In force	Term ends Oct 8, 2036	From the USPTO record

10 of 16 patents shown.

Pro members see all 16.

Pro members: see all 16 patents

Also on record, not counted in the 16: 4 patents in force now held by others · 33 lapsed for an unpaid fee · 8 ended at full term · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

11 pending · 18 abandoned · 45 no status recorded

List them